Related Experiment Videos
Propofol safely used in a neuroleptic malignant syndrome patient
J Rupreht1, A P Verkaaik, W Erdmann
1Department of Anaesthesiology, University Hospital, Erasmus University, Rotterdam, The Netherlands.
Anaesthesiologie Und Reanimation
|January 1, 1991
Abstract:
Anaesthetic regimens for patients with the poorly understood neuroleptic malignant syndrome (NMS) are not well outlined. In this case report, NMS and its questionable relation to malignant hyperpyrexia are outlined. Satisfactory use of total intravenous anaesthesia, based on propofol, in an NMS-susceptible patient is presented.
Insights
Anesthetic management for neuroleptic malignant syndrome (NMS) is unclear. This case report details the successful use of propofol-based total intravenous anesthesia in a patient susceptible to NMS.
Area of Science:
- Anesthesiology
- Neuroscience
- Pharmacology
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but serious adverse drug reaction.
- The pathophysiology and anesthetic management of NMS remain poorly understood.
- Its relationship with malignant hyperpythemia is debated, complicating anesthetic choices.
Observation:
- This case report focuses on an NMS-susceptible patient.
- The patient's susceptibility to NMS presented a significant anesthetic challenge.
- Standard anesthetic protocols for NMS are not well-established.
Findings:
- Total intravenous anesthesia (TIVA) utilizing propofol was successfully administered.
- Propofol-based TIVA provided a safe and effective anesthetic regimen.
- This approach demonstrated suitability for NMS-susceptible patients.
Implications:
- The findings suggest propofol-based TIVA as a viable anesthetic option for NMS.
- This case expands anesthetic possibilities for patients with NMS.
- Further research into NMS anesthetic management is warranted.